SAB Biotherapeutics (NASDAQ:SABS) Posts Quarterly Earnings Results, Beats Expectations By $0.44 EPS

SAB Biotherapeutics (NASDAQ:SABS) posted its quarterly earnings data on Friday. The company reported ($0.56) EPS for the quarter, topping analysts’ consensus estimates of ($1.00) by $0.44, Zacks reports. SAB Biotherapeutics had a negative return on equity of 94.37% and a negative net margin of 1,450.14%.

SAB Biotherapeutics Stock Up 4.1 %

SABS stock opened at $1.79 on Friday. The firm has a market cap of $16.63 million, a price-to-earnings ratio of -0.48 and a beta of 0.47. SAB Biotherapeutics has a 1-year low of $1.00 and a 1-year high of $5.01. The firm has a fifty day moving average price of $1.49 and a two-hundred day moving average price of $2.55. The company has a debt-to-equity ratio of 0.09, a current ratio of 3.69 and a quick ratio of 3.69.

Analyst Upgrades and Downgrades

A number of research firms have recently commented on SABS. HC Wainwright reaffirmed a “buy” rating and set a $6.00 price objective on shares of SAB Biotherapeutics in a research note on Tuesday, April 1st. Chardan Capital dropped their price target on shares of SAB Biotherapeutics from $25.00 to $20.00 and set a “buy” rating for the company in a research report on Tuesday, April 1st. Five investment analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock presently has an average rating of “Buy” and an average price target of $11.40.

SAB Biotherapeutics Company Profile

SAB Biotherapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at infectious diseases and immune and autoimmune disorders, including infectious diseases, influenza, CDI, type 1 diabetes, organ transplantation, and oncology, as well as immunology, gastroenterology, and respiratory diseases.